Group 1 - The Nipah virus outbreak in West Bengal, India has led to confirmed cases and significant market reactions, particularly in vaccine and diagnostic sectors, with several stocks experiencing price surges [1][2] - The Nipah virus, first identified in 1998, has a high fatality rate exceeding 40% and lacks effective treatments, which raises public health concerns and market volatility [2][3] - Despite initial market enthusiasm, the lack of confirmed cases in China and the limited geographical impact of the outbreak have resulted in a significant stock price correction for related companies [1][4] Group 2 - Companies like Capbio, Zhijiang Bio, and others have developed Nipah virus testing products, but the overall demand for testing has not increased significantly due to the outbreak, leading to continued financial pressure on these firms [4][10] - The medical testing industry, previously buoyed by COVID-19 testing, is now facing declining revenues as demand decreases, with many companies reporting substantial losses [9][10] - The vaccine sector is also under pressure, with companies like Zhifei and Watson facing intense competition and declining sales, leading to significant financial challenges [15][20] Group 3 - The overall performance of companies in the vaccine and diagnostic sectors is expected to remain under pressure due to economic cycles, increased competition, and regulatory changes affecting pricing and profitability [12][20] - The Nipah virus outbreak has not translated into increased orders for testing products from domestic companies, indicating a lack of substantial market opportunity arising from the situation [12][22] - Investors are advised to be cautious, as the Nipah virus may not provide the expected boost to the performance of the medical testing and vaccine industries, which are already struggling with profitability [22]

Core Viewpoint - The resignation of Wu Hongbo as the president of Kanghua Biological (300841) has been announced, effective immediately upon submission of his resignation report to the board of directors [1] Group 1: Leadership Changes - Wu Hongbo resigned from his position as president due to personal reasons, with his original term set from July 16, 2024, to July 15, 2027 [1] - Following Wu's resignation, he will not hold any position within the company [1] - The board of directors has authorized Fan Changyong, the executive vice president, to act as the president until a new president is appointed or until the current board's term ends, whichever comes first [1]

Core Viewpoint - Kanghua Biotech plans to acquire 100% equity of Nameixin Biotech to enhance its mRNA technology platform and accelerate vaccine development efficiency [1] Group 1: Acquisition Details - The company intends to subscribe to the new registered capital of Nameixin and acquire existing shares from current shareholders [1] - Upon completion of the transaction, Kanghua Biotech will hold 100% equity in Nameixin [1] Group 2: Strategic Implications - The acquisition will improve the company's biopharmaceutical strategic layout and accelerate the construction of advanced technology platforms [1] - The transaction is expected to enhance core competitiveness and leverage synergies in research, clinical, production, and commercialization between Kanghua Biotech and Nameixin [1] - It will expedite the industrialization process of in-development products and optimize resource allocation efficiency [1]

Core Viewpoint - The company announced the resignation of its president, Wu Hongbo, due to personal reasons, effective immediately upon delivery of the resignation report to the board of directors [1]. Group 1 - The board of directors received the resignation report from the president [1]. - Wu Hongbo will no longer hold any position within the company after his resignation [1].

Group 1 - The company announced that Mr. Wu Hongbo has resigned from his position as president due to personal reasons, with his original term set from July 16, 2024, to July 15, 2027 [1] - Following his resignation, Mr. Wu will not hold any position within the company [1] - The board of directors has authorized Mr. Fan Changyong, the executive vice president, to assume the responsibilities of the president [1] Group 2 - The investigation into the "Jie Wo Rui" redemption crisis on the Shuibei Gold platform revealed a 40-fold leverage bet, indicating that the platform incurs losses as gold prices rise [1] - Investors reported that the proposed redemption plan offers only 20% of the principal, which they find unacceptable [1]

证券代码：300841 证券简称：康华生物 公告编号：2026-005 成都康华生物制品股份有限公司 关于使用部分暂时闲置募集资金和自有资金 进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏, 并就其保证承担个别和连带的责任。 成都康华生物制品股份有限公司（以下简称"公司"）于2026年1月28日召 开第三届董事会第十三次会议，审议通过了《关于使用部分暂时闲置募集资金和 自有资金进行现金管理的议案》。现将有关情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准成都康华生物制品股份有限公司首次 公开发行股票的批复》（证监许可[2020]521 号）核准，并经深圳证券交易所同 意，公司首次公开发行人民币普通股（A 股）1,500.00 万股，每股面值人民币 1.00 元，每股发行价格为人民币 70.37 元，募集资金总额为人民币 1,055,550,000.00 元， 扣除相关发行费用后实际募集资金净额为人民币 980,973,000.00 元。募集资金已 于 2020 年 6 月 10 日划至公司指定账户。立信会计师事务所（特 ...

二、授权常务副总裁代行总裁职责情况 为确保公司在总裁岗位空缺期间经营管理工作的连续性和稳定性，结合当前 实际，公司于2026年1月28日召开第三届董事会第十三次会议，审议通过了《关 于授权常务副总裁代行总裁职责的议案》。公司董事会授权公司常务副总裁樊长 勇先生（简历详见附件）代行总裁职责，期限自本次董事会审议通过之日起，至 董事会聘任新任总裁之日或公司第三届董事会届满之日孰早时止。 证券代码：300841 证券简称：康华生物 公告编号：2026-006 成都康华生物制品股份有限公司 关于总裁辞职暨授权常务副总裁代行总裁职责的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏, 并就其保证承担个别和连带的责任。 一、总裁辞职情况 成都康华生物制品股份有限公司（以下简称"公司"）董事会近日收到公司 总裁吴红波先生的辞职报告。吴红波先生因个人原因辞去公司总裁职务，其原定 任期为2024年7月16日至2027年7月15日。吴红波先生的辞职报告自送达公司董事 会之日起生效，其将按照公司《董事、高级管理人员离职管理制度》做好工作交 接。辞去总裁职务后，吴红波先生不在公司担 ...

国联民生证券承销保荐有限公司 关于成都康华生物制品股份有限公司 使用部分暂时闲置募集资金和自有资金 进行现金管理的核查意见 国联民生证券承销保荐有限公司（以下简称"国联民生承销保荐"或"保荐 机构"）作为成都康华生物制品股份有限公司（以下简称"康华生物"、"公司"） 首次公开发行股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管 理办法》《上市公司募集资金监管规则》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》 等法律法规和规范性文件的规定，对康华生物使用部分暂时闲置募集资金和自有 资金进行现金管理事项进行审慎核查，核查意见如下： 一、募集资金基本情况 公司经中国证券监督管理委员会证监许可[2020]521号《关于核准成都康华 生物制品股份有限公司首次公开发行股票的批复》核准，首次公开发行人民币普 通股（A股）1,500.00万股，每股发行价为人民币70.37元，募集资金总额为人民 币105,555.00万元，扣除各项发行费用人民币7,457.70万元后，募集资金净额为人 民币98,097.30万元。募集资金到位情况业经立信会计师事务所（特 ...

证券代码：300841 证券简称：康华生物 公告编号：2026-004 成都康华生物制品股份有限公司 关于签署《投资意向书》暨关联交易的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏, 并就其保证承担个别和连带的责任。 特别提示： 1、 本次签订的《投资意向书》（以下简称"意向书"）为意向性协议，就 成都康华生物制品股份有限公司（以下简称"公司"）拟增资及受让纳美信（上 海）生物科技有限公司（以下简称"纳美信"）股权事项，交易相关各方将就核 心的交易条件、交易金额等进行商讨，并履行各自审批程序，决定是否签署正式 投资协议等文件。交易相关各方能否就意向书所涉及的合作事项后续签署实质性 协议并实施尚存在不确定性，请广大投资者谨慎投资，注意投资风险。 2、 本次签署的意向书属于意向性协议，除"保密"、"排他期"、"意向 金"、"适用法律及争议解决"和"约束力"条款外，不构成纳美信、纳美信现 有股东和公司之间具有约束力的协议，亦未设定涉及交易核心商业条款的具体权 利与义务，意向书的签订不会对公司当前财务数据及经营业绩产生重大影响，对 公司经营业绩的影响需视具 ...

证券代码：300841 证券简称：康华生物 公告编号：2026-003 成都康华生物制品股份有限公司 第三届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有虚 假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 成都康华生物制品股份有限公司（以下简称"公司"）第三届董事会第十三 次会议通知于2026年1月23日以专人送达、邮件等方式向全体董事发出，会议于 2026年1月28日以现场与线上相结合的方式召开；本次会议由董事长刘大伟先生 召集并主持，会议应出席董事11人，实际出席董事11人。本次会议的召集和召开 程序符合《中华人民共和国公司法》《成都康华生物制品股份有限公司章程》等 有关规定，会议合法、有效。 二、 董事会会议审议情况 （一）审议通过《关于签署<投资意向书>暨关联交易的议案》 经审议，董事会同意公司与纳美信（上海）生物科技有限公司及其部分现有 股东邓明先生、钱志康先生及上海浦信诚企业管理中心（有限合伙）签订《投资 意向书》。 本议案已经公司第三届董事会战略与发展委员会第二次会议审议通过。 本议案已经公司第三届董事会独立董事第十次专门会议审议通过。 具体 ...